REGN241220C1280000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Regeneron Reports Positive Results for Two Anti-coagulant Drugs
Express News | Regeneron Pharmaceuticals Inc - Regn7508 and Regn9933 Evaluated for Thrombosis Control
Express News | Regeneron Pharmaceuticals Inc - Phase 3 Program to Begin in 2025
Regeneron to Advance Two Factor XI Antibodies Into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
Leerink Partners Keeps Their Hold Rating on Regeneron (REGN)
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Express News | Regeneron Pharmaceuticals Shares Are Trading Higher After the Company Announced Its QUASAR Trial Investigating EYLEA HD Met Its Primary Endpoint for the Treatment of Patients With Macular Edema
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target
Express News | Bayer AG - Approximately 90% of Aflibercept 8 Mg Patients Were Extended to Every 8-Week Dosing and Maintained Their Interval Through 36 Weeks
Express News | Regeneron Pharmaceuticals Inc - Supplementary Biologics License Application Planned for Q1 2025
Express News | Regeneron Pharmaceuticals Inc - Safety Data Consistent With Known Eylea Hd and Eylea Profiles
Express News | Eylea Hd® (Aflibercept) Injection 8 Mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision With Extended Dosing Intervals in Patients With Macular Edema Following Retinal Vein Occlusion
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Regeneron Pharma Price Target Announced at $165.00/Share by Canaccord Genuity